Embed Size (px)
Citation preview
Herramientas de evaluación del
beneficioMª Estela Moreno MartínezAdjunta Farmacia, BCOP
Hospital de la Santa Creu i Sant PauBarcelona
1
¿Beneficio?
3
3
BENEFICIO
QoL
SLPSG
TasaRespuesta
4
4
Para el PACIENTE...
CurarseVivir más
Vivir mejor
Medir…
6
6
BENEFICIO
QoL
SLPSG
TasaRespuesta
¿Cuántos meses?
Adyuvanciavs
metastásica¿Escala general vs específica?
¿Estabilización?
¿No pérdida QoL?Efectos adversos tolerables
¿Técnica?
¿HR?
8
8
9
9
Schnniper LE, et al. JCO 2015;33(23):2963-77 Schnniper LE, et al. JCO 2016;34(24):2925-34
10Adyuvancia
Schnniper LE, et al. JCO 2016;34(24):2925-34
11
11
Cherny NI et al. Annals of Oncology 2015;26:1547-73Cherny NI et al. Annals of Oncology 2017;28:2340-66
12
Cherny NI et al. Annals of Oncology 2015;26:1547-73Cherny NI et al. Annals of Oncology 2017;28:2340-66
13
13
14
14
15
15Kiesewetter B, et al. ESMO Open 2020;5;e000611
16
16
17
Cherny NI, et al. Comparative assessment of clinical benefit using the ESMO. Magnitude of clinical benefit scale versión 1.1 and the ASCO value frameworknet health benefit score. JCO 2018;37:336-49
18
Cherny NI, et al. Comparative assessment of clinical benefit using the ESMO. Magnitude of clinical benefit scale versión 1.1 and the ASCO value frameworknet health benefit score. JCO 2018;37:336-49
19
Cherny NI, et al. Comparative assessment of clinical benefit using the ESMO. Magnitude of clinical benefit scale versión 1.1 and the ASCO value frameworknet health benefit score. JCO 2018;37:336-49
20
20
Campolina AG. Value-based medicine in oncology: theimportance of perspective in the emerging value frameworks. Clinics 2018;73(suppl 1):e470s
21
Drug Assesment Framework
21
Ezeife DA, et al. Value assessment of Oncology drugs using a weighted Criterion-based approach. Cancer 2019;0:1-11
Beneficio Clínico
22
22
Ezeife DA, et al. Value assessment of Oncology drugs using a weighted Criterion-based approach. Cancer 2019;0:1-11
23
23
Ezeife DA, et al. Value assessment of Oncology drugs using a weighted Criterion-based approach. Cancer 2019;0:1-11
24
Multi Criteria Decision Analysis
24
Campolina AG. Value-based medicine in oncology: theimportance of perspective in the emerging value frameworks. Clinics 2018;73(suppl 1):e470s
25
25
1
